Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors
Kestra Medical Technologies, a privately held wearable medical device and digital healthcare company, has announced the appointment of Raymond W. Cohen to its board of directors as an independent member. Cohen, with over 40 years of life sciences industry experience, is currently the CEO and board member of Axonics Inc. (Nasdaq: AXNX), which recently agreed to be acquired by Boston Scientific for $3.7 billion.
Brian Webster, President & CEO of Kestra, highlighted Cohen's extensive experience in external defibrillation and commercial growth strategies as valuable assets for the company. Kestra recently closed a $196 million funding round to support commercial expansion and advance its mission of protecting at-risk patients with its wearable cardioverter defibrillator. The funding was co-led by Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Funds, with participation from new and long-term investors.
Kestra Medical Technologies, un'azienda privata specializzata in dispositivi medici indossabili e sanità digitale, ha annunciato la nomina di Raymond W. Cohen nel suo consiglio di amministrazione come membro indipendente. Cohen, con oltre 40 anni di esperienza nell'industria delle scienze della vita, è attualmente CEO e membro del consiglio di Axonics Inc. (Nasdaq: AXNX), che ha recentemente concordato di essere acquisita da Boston Scientific per 3,7 miliardi di dollari.
Brian Webster, Presidente e CEO di Kestra, ha evidenziato l'ampia esperienza di Cohen nella defibrillazione esterna e nelle strategie di crescita commerciale come risorse preziose per l'azienda. Kestra ha recentemente chiuso un round di finanziamento di 196 milioni di dollari per sostenere l'espansione commerciale e promuovere la sua missione di proteggere i pazienti a rischio con il suo defibrillatore cardioverter indossabile. Il finanziamento è stato co-guidato da Andera Partners, Ally Bridge Group, Longitude Capital e Omega Funds, con la partecipazione di nuovi investitori e investitori di lungo termine.
Kestra Medical Technologies, una empresa privada de dispositivos médicos portátiles y atención digital en salud, ha anunciado el nombramiento de Raymond W. Cohen como miembro independiente de su junta directiva. Cohen, con más de 40 años de experiencia en la industria de las ciencias de la vida, es actualmente el CEO y miembro de la junta de Axonics Inc. (Nasdaq: AXNX), que recientemente acordó ser adquirida por Boston Scientific por 3.7 mil millones de dólares.
Brian Webster, Presidente y CEO de Kestra, destacó la amplia experiencia de Cohen en desfibrilación externa y estrategias de crecimiento comercial como activos valiosos para la empresa. Kestra cerró recientemente una ronda de financiamiento de 196 millones de dólares para apoyar la expansión comercial y avanzar en su misión de proteger a los pacientes en riesgo con su desfibrilador cardiovertidor portátil. El financiamiento fue co-liderado por Andera Partners, Ally Bridge Group, Longitude Capital y Omega Funds, con la participación de nuevos inversores y de inversores a largo plazo.
Kestra Medical Technologies는 웨어러블 의료 기기 및 디지털 헬스케어 회사로, 독립 이사로 레이먼드 W. 코헨을 이사회에 임명했다고 발표했습니다. 코헨은 생명 과학 산업에서 40년 이상의 경험을 가지고 있으며, 현재 Axonics Inc. (Nasdaq: AXNX)의 CEO이자 이사입니다. Axonics는 최근 37억 달러에 Boston Scientific에 인수되기로 합의했습니다.
Kestra의 사장 겸 CEO인 브라이언 웹스터는 코헨의 외부 제세동 및 상업적 성장 전략에 대한 폭넓은 경험이 회사에 귀중한 자산이 될 것이라고 강조했습니다. Kestra는 최근 1억 9,600만 달러의 자금 조달 라운드를 종료하여 상업적 확장을 지원하고 웨어러블 심장 제세동기로 위험에 처한 환자를 보호하는 사명을 수행하고 있습니다. 이 자금 조달은 Andera Partners, Ally Bridge Group, Longitude Capital 및 Omega Funds가 공동 주도했으며, 신규 및 장기 투자자들이 참여했습니다.
Kestra Medical Technologies, une entreprise privée spécialisée dans les dispositifs médicaux portables et la santé numérique, a annoncé la nomination de Raymond W. Cohen en tant que membre indépendant de son conseil d'administration. Cohen, qui possède plus de 40 ans d'expérience dans l'industrie des sciences de la vie, est actuellement PDG et membre du conseil de Axonics Inc. (Nasdaq: AXNX), qui a récemment accepté d'être acquis par Boston Scientific pour 3,7 milliards de dollars.
Brian Webster, président et PDG de Kestra, a souligné que l'expérience approfondie de Cohen en matière de défibrillation externe et de stratégies de croissance commerciale constituait des atouts précieux pour l'entreprise. Kestra a récemment clôturé un tour de financement de 196 millions de dollars pour soutenir son expansion commerciale et faire avancer sa mission de protection des patients à risque grâce à son défibrillateur cardioverseur portable. Le financement a été co-dirigé par Andera Partners, Ally Bridge Group, Longitude Capital et Omega Funds, avec la participation de nouveaux investisseurs et d'investisseurs de longue date.
Kestra Medical Technologies, ein privat geführtes Unternehmen für tragbare medizinische Geräte und digitale Gesundheitslösungen, hat die Ernennung von Raymond W. Cohen als unabhängiges Mitglied in seinen Vorstand bekannt gegeben. Cohen bringt über 40 Jahre Erfahrung in der Biowissenschaftsbranche mit und ist derzeit CEO und Vorstandsmitglied von Axonics Inc. (Nasdaq: AXNX), das kürzlich einer Übernahme durch Boston Scientific für 3,7 Milliarden Dollar zugestimmt hat.
Brian Webster, Präsident und CEO von Kestra, betonte, dass Cohens umfassende Erfahrung in der externen Defibrillation und kommerziellen Wachstumsstrategien wertvolle Vorteile für das Unternehmen darstellt. Kestra hat kürzlich eine Finanzierungsrunde über 196 Millionen Dollar abgeschlossen, um das kommerzielle Wachstum zu unterstützen und seine Mission fortzusetzen, gefährdete Patienten mit seinem tragbaren Herzdefibrillator zu schützen. Die Finanzierung wurde gemeinsam von Andera Partners, Ally Bridge Group, Longitude Capital und Omega Funds geleitet, mit der Beteiligung neuer und langjähriger Investoren.
- Appointment of Raymond W. Cohen, an experienced medical device executive, to the board of directors
- Recent closure of a $196 million funding round for commercial expansion
- Potential to compete in the $1B revenue wearable defibrillator market
- None.
Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire)
Brian Webster, President & CEO of Kestra said, “Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commercializing emerging medical technologies. Mr. Cohen’s extensive experience in the external defibrillation field and commercial growth strategies will be invaluable to the Kestra team. His track record of strategic exits for both public and private companies, including Axonics’ successful IPO and shareholder value creation as a public entity will accrue to our benefit as we envision the future of Kestra. On behalf of the Kestra stakeholders, we are delighted to welcome him on the board of Kestra.”
Mr. Cohen is an accredited public company director with more than 40 years of life sciences industry experience. He currently serves as CEO and board member at
Raymond W. Cohen said, “Kestra has a world-class wearable defibrillator product and is poised to compete aggressively in this former monopoly market which is estimated to be in the
Kestra Medical Technologies, Inc., recently closed a
About Kestra
Kestra Medical Technologies, Inc. is a privately held wearable medical device and digital healthcare company that protects cardiac patients with diagnostic monitoring and therapeutic technologies that are intuitive, intelligent, and mobile. Kestra was founded in 2014 by leaders from the external (AED) and implantable (ICD) defibrillation industries. Based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725221367/en/
Debra Schotz
Kestra Medical Technologies, Inc.
(425) 384-3523
debra.schotz@kestramedical.com
Source: Kestra Medical Technologies, Inc.
FAQ
Who is Raymond W. Cohen and why is his appointment significant for Kestra Medical Technologies (AXNX)?
What was the size of Kestra Medical Technologies' recent funding round and what will it be used for?
What is the estimated market size for wearable defibrillators that Kestra Medical Technologies is targeting?
Which companies led the recent funding round for Kestra Medical Technologies?
